Turisteron

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 462663

CAS#: 28913-23-7

Description: Turisteron is an estrogen medication which has been used in birth control pills for women and in the treatment of prostate cancer in men. It has also been investigated in the treatment of breast cancer in women.

Chemical Structure

img
Turisteron
CAS# 28913-23-7
Instruction

Theoretical Analysis

MedKoo Cat#: 462663
Name: Turisteron
CAS#: 28913-23-7
Chemical Formula: C23H30O4S
Exact Mass: 402.19
Molecular Weight: 402.549
Elemental Analysis: C, 68.63; H, 7.51; O, 15.90; S, 7.96

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Turisteron; Ethinyl estradiol isopropylsulfonate;

IUPAC/Chemical Name: (8R,9S,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl propane-2-sulfonate

InChi Key: KPEUDULLQDHKAZ-VROINQGHSA-N

InChi Code: InChI=1S/C23H30O4S/c1-5-23(24)13-11-21-20-8-6-16-14-17(27-28(25,26)15(2)3)7-9-18(16)19(20)10-12-22(21,23)4/h1,7,9,14-15,19-21,24H,6,8,10-13H2,2-4H3/t19-,20-,21+,22+,23+/m1/s1

SMILES Code: CC(S(=O)(Oc1cc2c([C@H]3CC[C@]4([C@H]([C@@H]3CC2)CC[C@]4(C#C)O)C)cc1)=O)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 402.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Böhm WD, Gorski J, Geissler W, Illig HD, Koch R. Zum klinischen Wert von Athinylöstradiolsulfonat (Turisteron)--Langzeitergebnisse einer randomisierten Verbundstudie [Clinical value of ethinyl estradiol sulfonate (Turisteron)--long- term results of a randomized compound study]. Z Urol Nephrol. 1987 Mar;80(3):159-64. German. PMID: 2440199.

2: Stahl F, Schnorr D, Bär CM, Fröhlich G, Dörner G. Suppression of plasma androgen levels with a combination therapy of depot-estrogen (Turisteron) and Dexamethasone in patients with prostatic cancer. Exp Clin Endocrinol. 1989;94(3):239-43. doi: 10.1055/s-0029-1210905. PMID: 2630306.

3: Dörner G, Schnorr D, Stahl F, Rohde W. Successful treatment of prostatic cancer with the orally active depot estrogen ethinylestradiol sulfonate (Turisteron). Exp Clin Endocrinol. 1985 Dec;86(2):190-6. doi: 10.1055/s-0029-1210486. PMID: 3912197.

4: Gürtler R, Tanneberger S, Bodek B, Morack G. Turisteron: Klinische Erfahrungen mit einem Depot-Ostrogen bei der Behandlung des metastasierenden Mammakarzinoms [Clinical experience with the depot estrogen Turisteron in the treatment of metastatic breast cancer (author's transl)]. Arch Geschwulstforsch. 1982;52(2):129-39. German. PMID: 7103689.

5: Klebingat KJ, Panzig E, Lorenz G, Steinhauser I, Fiedler R. Die zellvermittelte Immunität (CMI) beim Prostatakarzinom unter Einfluss von Cytonal, Estrazyt und Turisteron [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron]. Z Urol Nephrol. 1987 Mar;80(3):139-47. German. PMID: 3300097.

6: Drawz B, Hoffmann L, Drawz G, Russbüldt R. Erfahrungen bei der Behandlung des fortgeschrittenen Prostatakarzinoms mit Turisteron unter besonderer Berücksichtigung kardiovaskulärer Komplikationen [Experiences in the treatment of advanced prostatic cancer using Turisteron with special reference to cardiovascular complications]. Z Urol Nephrol. 1987 Mar;80(3):171-5. German. PMID: 3604473.

7: Stahl F, Schnorr D, Rohde W, Dörner G. Auffallend starke Hemmung des freien, biologisch aktiven Testosteronspiegels durch Behandlung mit Turisteron bei Patienten mit Prostatakarzinom [Inhibition of the free, biologically active testosterone level by Turisteron in patients with prostate cancer]. Z Urol Nephrol. 1987 Mar;80(3):135-8. German. PMID: 3604472.

8: Guddat HM, Schnorr D, Zemke F. Erste Ergebnisse der multizentrischen klinischen Prüfung Stufe IV von Turisteron zur Therapie des Prostatakarzinoms [Initial results of a phase IV multicenter clinical trial of Turisteron in the treatment of prostate cancer]. Z Urol Nephrol. 1987 Mar;80(3):165-70. German. PMID: 3300098.

9: Guddat HM, Schnorr D, Dörner G, Stahl F, Rohde W. Das Verhalten der Serumspiegel von LH, FSH, Gesamttestosteron (GT), freiem Testosteron (FT) und SHBG unter der Therapie des Prostatakarzinoms mit Turisteron (Ethinylestradiolsulfonat) [Behavior of LH, FSH, total testosterone, free testosterone and SHBG serum levels in the therapy of prostatic cancer with Turisteron (ethinyl estradiol sulfonate)]. Z Urol Nephrol. 1987 Dec;80(12):665-8. German. PMID: 3126615.

10: Schnorr D, Dörner G, Stahl F, Rohde W, Guddat HM. Zur konservativen Therapie des Prostatakarzinoms mit Turisteron [Conservative therapy of prostate cancer using Turisteron]. Z Urol Nephrol. 1987 Mar;80(3):149-57. German. PMID: 3111122.

11: Sladczyk E. Klinische Erfahrungen bei der Anwendung von Turisteron zur Behandlung des Prostatakarzinoms [Clinical experience using Turisteron in the treatment of prostatic cancer]. Z Urol Nephrol. 1987 Mar;80(3):181-3. German. PMID: 3604475.

12: Vachalovský V, Vomácka V. Turisteron v lécbĕ pokrocilého karcinomu prostaty [Turisteron in the treatment of advanced carcinoma of the prostate]. Rozhl Chir. 1985 Nov;64(11):718-22. Czech. PMID: 4089702.

13: Zade W, Schott H. Leberschäden unter der Hormontherapie des Prostatakarzinoms [Liver damage in hormone therapy of prostate cancer]. Z Urol Nephrol. 1987 Mar;80(3):177-9. German. PMID: 3604474.

14: Langkopf B. Zur Therapie des fortgeschrittenen Prostatakarzinoms [Therapy of advanced prostate cancer]. Z Urol Nephrol. 1987 Mar;80(3):121-4. German. PMID: 3111121.